These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 33754721)

  • 1. Structure-Based Identification of Potent Lysine-Specific Demethylase 1 Inhibitor Peptides and Temporary Cyclization to Enhance Proteolytic Stability and Cell Growth-Inhibitory Activity.
    Kitagawa H; Kikuchi M; Sato S; Watanabe H; Umezawa N; Kato M; Hisamatsu Y; Umehara T; Higuchi T
    J Med Chem; 2021 Apr; 64(7):3707-3719. PubMed ID: 33754721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of lysine-specific demethylase 1 inhibitor peptide by redox-controlled cleavage of a traceless linker.
    Amano Y; Umezawa N; Sato S; Watanabe H; Umehara T; Higuchi T
    Bioorg Med Chem; 2017 Feb; 25(3):1227-1234. PubMed ID: 28065500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, Synthesis, and In Vitro Evaluation of Novel Histone H3 Peptide-Based LSD1 Inactivators Incorporating α,α-Disubstituted Amino Acids with γ-Turn-Inducing Structures.
    Ota Y; Kakizawa T; Itoh Y; Suzuki T
    Molecules; 2018 May; 23(5):. PubMed ID: 29734782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Annual review of lysine-specific demethylase 1 (LSD1/KDM1A) inhibitors in 2021.
    Song Y; Zhang H; Yang X; Shi Y; Yu B
    Eur J Med Chem; 2022 Jan; 228():114042. PubMed ID: 34915312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Histone H3 peptide based LSD1-selective inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Tsumoto H; Suzuki T
    Bioorg Med Chem Lett; 2015 May; 25(9):1925-8. PubMed ID: 25827526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone H3 peptides incorporating modified lysine residues as lysine-specific demethylase 1 inhibitors.
    Kakizawa T; Ota Y; Itoh Y; Suzuki T
    Bioorg Med Chem Lett; 2018 Jan; 28(2):167-169. PubMed ID: 29198865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Covalent Peptide LSD1 Inhibitor Specifically Recognizes Cys360 in the Enzyme-Active Region.
    Luo Q; Ma Y; Liang H; Feng Y; Liu N; Lian C; Zhu L; Ye Y; Liu Z; Hou Z; Chen S; Wang Y; Dai C; Song C; Zhang M; He Z; Xing Y; Zhong W; Li S; Wu J; Lu F; Yin F; Li Z
    J Med Chem; 2023 Nov; 66(22):15409-15423. PubMed ID: 37922441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development and crystallographic evaluation of histone H3 peptide with N-terminal serine substitution as a potent inhibitor of lysine-specific demethylase 1.
    Amano Y; Kikuchi M; Sato S; Yokoyama S; Umehara T; Umezawa N; Higuchi T
    Bioorg Med Chem; 2017 May; 25(9):2617-2624. PubMed ID: 28336409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fluorinated tranylcypromine analogues as inhibitors of lysine-specific demethylase 1 (LSD1, KDM1A).
    Borrello MT; Schinor B; Bartels K; Benelkebir H; Pereira S; Al-Jamal WT; Douglas L; Duriez PJ; Packham G; Haufe G; Ganesan A
    Bioorg Med Chem Lett; 2017 May; 27(10):2099-2101. PubMed ID: 28390942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis and evaluation of γ-turn mimetics as LSD1-selective inhibitors.
    Ota Y; Miyamura S; Araki M; Itoh Y; Yasuda S; Masuda M; Taniguchi T; Sowa Y; Sakai T; Itami K; Yamaguchi J; Suzuki T
    Bioorg Med Chem; 2018 Feb; 26(3):775-785. PubMed ID: 29331452
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of SNAIL1 Peptide-Based Irreversible Lysine-Specific Demethylase 1-Selective Inactivators.
    Itoh Y; Aihara K; Mellini P; Tojo T; Ota Y; Tsumoto H; Solomon VR; Zhan P; Suzuki M; Ogasawara D; Shigenaga A; Inokuma T; Nakagawa H; Miyata N; Mizukami T; Otaka A; Suzuki T
    J Med Chem; 2016 Feb; 59(4):1531-44. PubMed ID: 26700437
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 4-Hydroxy-3-methylbenzofuran-2-carbohydrazones as novel LSD1 inhibitors.
    He X; Gao Y; Hui Z; Shen G; Wang S; Xie T; Ye XY
    Bioorg Med Chem Lett; 2020 May; 30(10):127109. PubMed ID: 32201021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia.
    Feng Z; Yao Y; Zhou C; Chen F; Wu F; Wei L; Liu W; Dong S; Redell M; Mo Q; Song Y
    J Hematol Oncol; 2016 Mar; 9():24. PubMed ID: 26970896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery and synthesis of novel indole derivatives-containing 3-methylenedihydrofuran-2(3H)-one as irreversible LSD1 inhibitors.
    Liu HM; Suo FZ; Li XB; You YH; Lv CT; Zheng CX; Zhang GC; Liu YJ; Kang WT; Zheng YC; Xu HW
    Eur J Med Chem; 2019 Aug; 175():357-372. PubMed ID: 31096156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-based design and discovery of potent and selective lysine-specific demethylase 1 (LSD1) inhibitors.
    Nie Z; Shi L; Lai C; Severin C; Xu J; Del Rosario JR; Stansfield RK; Cho RW; Kanouni T; Veal JM; Stafford JA; Chen YK
    Bioorg Med Chem Lett; 2019 Jan; 29(1):103-106. PubMed ID: 30409536
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annual review of LSD1/KDM1A inhibitors in 2020.
    Fu DJ; Li J; Yu B
    Eur J Med Chem; 2021 Mar; 214():113254. PubMed ID: 33581557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New tranylcypromine derivatives containing sulfonamide motif as potent LSD1 inhibitors to target acute myeloid leukemia: Design, synthesis and biological evaluation.
    Liang L; Wang H; Du Y; Luo B; Meng N; Cen M; Huang P; Ganesan A; Wen S
    Bioorg Chem; 2020 Jun; 99():103808. PubMed ID: 32334189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase.
    Tortorici M; Borrello MT; Tardugno M; Chiarelli LR; Pilotto S; Ciossani G; Vellore NA; Bailey SG; Cowan J; O'Connell M; Crabb SJ; Packham G; Mai A; Baron R; Ganesan A; Mattevi A
    ACS Chem Biol; 2013 Aug; 8(8):1677-82. PubMed ID: 23721412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclic peptide inhibitors of lysine-specific demethylase 1 with improved potency identified by alanine scanning mutagenesis.
    Kumarasinghe IR; Woster PM
    Eur J Med Chem; 2018 Mar; 148():210-220. PubMed ID: 29459279
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [1,2,3]Triazolo[4,5-d]pyrimidine derivatives incorporating (thio)urea moiety as a novel scaffold for LSD1 inhibitors.
    Li ZH; Ma JL; Liu GZ; Zhang XH; Qin TT; Ren WH; Zhao TQ; Chen XH; Zhang ZQ
    Eur J Med Chem; 2020 Feb; 187():111989. PubMed ID: 31881456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.